IDEAYA Biosciences (FRA:30J) Total Liabilities : €62.02 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IDEAYA Biosciences Total Liabilities?

IDEAYA Biosciences's Total Liabilities for the quarter that ended in Dec. 2024 was €62.02 Mil.

IDEAYA Biosciences's quarterly Total Liabilities increased from Jun. 2024 (€39.02 Mil) to Sep. 2024 (€53.57 Mil) and increased from Sep. 2024 (€53.57 Mil) to Dec. 2024 (€62.02 Mil).

IDEAYA Biosciences's annual Total Liabilities declined from Dec. 2022 (€36.36 Mil) to Dec. 2023 (€25.88 Mil) but then increased from Dec. 2023 (€25.88 Mil) to Dec. 2024 (€62.02 Mil).

IDEAYA Biosciences Total Liabilities Historical Data

The historical data trend for IDEAYA Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEAYA Biosciences Total Liabilities Chart

IDEAYA Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

82.20

70.65

36.36

25.88

62.02

IDEAYA Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															25.88	24.12	39.02	53.57	62.02

IDEAYA Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

IDEAYA Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	43.998	+	(18.024	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	62.02

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1073.507	-	1011.485
	=	62.02

IDEAYA Biosciences's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	43.998	+	(18.024	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	62.02

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	1073.507	-	1011.485
	=	62.02

IDEAYA Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of IDEAYA Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEAYA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IDEAYA Biosciences Inc (FRA:30J) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

IDYA:USA

Address

5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.ideayabio.com

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

IDEAYA Biosciences Headlines

No Headlines